Results 161 to 170 of about 32,756 (253)

Cardiovascular‐Kidney‐Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular‐kidney‐metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition.
Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S. Jhund, Paul R. Kalra, Hongtu Zhu, David C. Wheeler, Geraint Roberts, Martin R. Cowie, Andrew H. Briggs   +10 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology. [PDF]

Acta Physiol (Oxf)
Ruiz MA, Furquim THDC, Davaanyam D, Williams NR, Polotsky VY, Amorim MR.   +5 more
europepmc   +1 more source

T2D Management Among a Community Clinic Patient Sample After California's May 2022 Medicaid Expansion

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In May 2022, California expanded its Medicaid program (‘Medi‐Cal’) to all low‐income adults over 50 years, regardless of immigration status. We compare haemoglobin A1c (HbA1c) and body mass index (BMI) among undocumented patients with Type 2 diabetes mellitus (T2D) in a primary care setting before and after the expansion.
Annie E. Ro, Jung Min Choi, Celina Morales, Nicole Tavares Kuhn, Cecilia Wu, Luohua Jiang   +5 more
wiley   +1 more source

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study. [PDF]

ACR Open Rheumatol
Frier K, Dietl M, Aronson S, Dhani J, James K, Betensky D, Selzer F, Losina E, Katz JN, Kim JS, Weiss-Laxer NS.   +10 more
europepmc   +1 more source

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases. [PDF]

Rheumatology (Oxford)
Karacabeyli D, Lacaille D.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You   +5 more
wiley   +1 more source

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Tamkeen Khan, Stavros Tsipas, Fleetwood Loustalot, Lindsay Zasadzinski, Klodiana Myftari, Alyson B. Goodman, Gregory D. Wozniak   +6 more
doaj   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity ...
Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski   +6 more
wiley   +1 more source